RecruitingNCT05597709

Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China

Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study

Sponsor

Wuxi Hisky Medical Technology Co Ltd

Enrollment

2,900 participants

Start Date

Jul 1, 2022

Study Type

OBSERVATIONAL

Conditions

Metabolic Associated Fatty Liver Disease Type 2 Diabetes Mellitus in Remission

Summary

In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how common a type of fatty liver disease called MAFLD (metabolic-associated fatty liver disease) is among people with type 2 diabetes in Jiangsu Province, China. It uses a non-invasive device to measure liver fat and aims to understand the link between diabetes and liver disease. **You may be eligible if...** - You have been diagnosed with type 2 diabetes - You are willing to have your liver fat measured using the iLivTouch device - You are able to give written informed consent **You may NOT be eligible if...** - You have a type of diabetes other than type 2 (e.g., type 1, gestational) - You have another known cause of liver disease (such as alcohol-related or viral hepatitis) - You have a condition that would make the liver test inaccurate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREUltrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination

Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination

Locations(1)

Zhongda Hospital, Medical School, Southeast University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05597709

Related Trials